- Home
- NXL vs GENK Comparison
NXL vs GENK Comparison
Compare NXL & GENK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXL | GENK |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Medical Specialities | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 9.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NXL | GENK |
|---|---|---|
| Price | $0.41 | $1.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $5.67 |
| AVG Volume (30 Days) | ★ 208.0K | 28.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | N/A | ★ 62.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $208,380,000.00 |
| Revenue This Year | $38.28 | $8.46 |
| Revenue Next Year | $185.71 | $8.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.12 |
| 52 Week Low | $0.37 | $1.50 |
| 52 Week High | $2.57 | $6.50 |
Technical Indicators
Market Signals| Indicator | NXL | GENK |
|---|---|---|
| Relative Strength Index (RSI) | 36.93 | 42.99 |
| Support Level | $0.37 | $1.66 |
| Resistance Level | $0.62 | $2.55 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 8.14 | 42.00 |
Price Performance
Historical ComparisonAbout NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.